Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C

Trial Profile

Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Boceprevir (Primary) ; Narlaprevir
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 17 Nov 2014 Status changed from completed to discontinued according to ClinicalTrials.gov record.
    • 20 Oct 2014 Trial status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 25 Sep 2014 Planned End Date changed from 1 May 2015 to 1 Sep 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top